BDBM465303 US10793564, Compound 92::US11419869, Compound 92::US11560376, Compound 92::US20230271960, Compound 92::US20230293519, Compound 92

SMILES OC(=O)[C@H](CCN(CCCCc1ccc2CCCNc2n1)CCOc1ccccc1)Nc1ccnc(n1)C(F)(F)F

InChI Key InChIKey=BJXDZMMLRLXKIE-UHFFFAOYSA-N

Data  5 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 465303   

TargetIntegrin alpha-5/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465303(US10793564, Compound 92 | US11560376, Compound 92 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465303(US10793564, Compound 92 | US11560376, Compound 92 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465303(US10793564, Compound 92 | US11560376, Compound 92 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465303(US10793564, Compound 92 | US11560376, Compound 92 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465303(US10793564, Compound 92 | US11560376, Compound 92 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent